StockData

GRI Bio vs Pliant Therapeutics

GRI and PLRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRI and PLRX compare

Pliant Therapeutics is the larger company, worth 12 times as much as GRI Bio ($43.2M against $3.7M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRIPLRX
Size and price
Market cap$3.7M$43.2M
Share price$1.70$0.697
Change, 1 year−96.8%−61.3%
Change, 5 years−100%−95.4%
Beta (5Y)0.751.00
Employees449
StockData Score
Total score66
Valuation score11
Growth score00
Performance score01 (better)
Health score5 (better)4
Dividend score00
Valuation
P/B0.4×0.3× (better)
FCF yield–−155%
Profitability
Return on equity−145%−55.3% (better)
Financial health
Debt / equity0.000.00
Interest coverage–−698.2×
Current ratio10.21 (better)8.05
Altman Z-score−7.38 (better)−7.99
Piotroski F-score3 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions4.3%77.7%
Held by insiders26.2%13.0%
Insider net buying, 12 months–−$164K
Short interest, % of float4.1%9.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.